Neurogene (NGNE) Stock Forecast & Price Target

Compare

564 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

NGNE Analyst Ratings

Strong Buy

7 Buy

0 Hold

0 Sell

Based on 7 analysts giving stock ratings to

Neurogene

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

NGNE Stock 12 Month Forecast

Average Price Target

$46.75

▲(133.52% Upside)

Based on 7 Wall Street analysts offering 12 month price targets for Neurogene in the last 3 months. The average price target is $46.75 with a high forecast of $70.00 and a low forecast of $26.00. The average price target represents a 133.52% change from the last price of $20.02.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"8":"$8","71":"$71","23.75":"$23.8","39.5":"$39.5","55.25":"$55.3"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":70,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$70.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":46.75,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$46.75</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":26,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$26.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[8,23.75,39.5,55.25,71],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Nov<br/>2024","6":"Feb<br/>2025","9":"May<br/>2025","12":"Aug<br/>2025","25":"Aug<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,21.78,25.48923076923077,29.19846153846154,32.90769230769231,36.61692307692308,40.326153846153844,44.035384615384615,47.744615384615386,51.45384615384616,55.16307692307692,58.87230769230769,62.581538461538464,66.29076923076923,{"y":70,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,21.78,23.700769230769232,25.621538461538464,27.542307692307695,29.463076923076926,31.383846153846157,33.30461538461539,35.22538461538461,37.14615384615385,39.066923076923075,40.98769230769231,42.90846153846154,44.82923076923077,{"y":46.75,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,21.78,22.104615384615386,22.42923076923077,22.753846153846155,23.07846153846154,23.403076923076924,23.72769230769231,24.052307692307693,24.376923076923077,24.701538461538462,25.026153846153846,25.35076923076923,25.675384615384615,{"y":26,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":40.62,"date":1719792000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":40.51,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 19,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":39.94,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":46.07,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 25,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 7</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":24.57,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 20,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 7</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":22.86,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 9</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":15.85,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":17.69,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":9.66,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 6</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":15.4,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 7</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":17.75,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 6</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":19.19,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 21,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":21.78,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target$70.00

Average Price Target$46.75

Lowest Price Target$26.00

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

Paul Matteis

Stifel Nicolaus

$46

Buy

129.77%

Upside

Reiterated

08/14/25

Stifel Nicolaus Sticks to Their Buy Rating for Neurogene (NGNE)

Albert Lowe

Craig-Hallum

―

Buy

―

Reiterated

08/13/25

Craig-Hallum Sticks to Their Buy Rating for Neurogene (NGNE)

Ritu Baral

TD Cowen

―

Buy

―

Reiterated

08/12/25

Positive Outlook for Neurogene: Buy Rating Affirmed Amid Clinical Progress and Strong Financial Position

Sami Corwin

William Blair

―

Buy

―

Reiterated

08/12/25

William Blair Sticks to Its Buy Rating for Neurogene (NGNE)

Mani Foroohar

Leerink Partners

$72→$70

Buy

249.65%

Upside

Reiterated

08/12/25

Neurogene's Clinical Progress and Financial Resilience Underpin Buy Rating Despite Regulatory ChallengesWe update our model for financial disclosures, modestly increase R&D for pivotal costs and nudge EU/RoW launch to 2030 (from 2029) as we await clarity on OUS regulatory pathway, which decreases our PT to $70 (from $72). Reiterate OP.

Mitchell Kapoor

H.C. Wainwright

$45

Buy

124.78%

Upside

Reiterated

08/12/25

Neurogene's NGN-401 Gains Favorable Buy Rating Amid Promising Trial Design and Strong Safety ProfileValuation and Risks. Using a 13% discount rate and 2% terminal growth rate, our discounted cash flow (DCF)-based analysis has resulted in an estimated enterprise value of $770M. We ascribe a 35% probability of approval to NGN-401 in Rett syndrome. Assuming 23M fully-diluted shares outstanding, we derive a 12-month price objective of $45 per share, which includes the forecasted cash position. We conservatively do not model any expansion into other indications or pipeline programs beyond NGN-401, which may drive upside to our valuation.

Evan Seigerman

BMO Capital

$22→$26

Buy

29.87%

Upside

Reiterated

06/30/25

Optimistic Outlook for Neurogene's NGN-401 in Rett Syndrome Treatment Boosts Buy Rating

Joel Beatty

Robert W. Baird

$38→$24

Hold

19.88%

Upside

Downgraded

05/16/25

Cautious Hold Rating on Neurogene Due to Regulatory Uncertainty and Data Quality Concerns for NGN-401

Dex Genotek

TR | OpenAI - 4o

―

Sell

―

Reiterated

05/01/25

AI Generated ArticleAI Generated Article

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

Paul Matteis

Stifel Nicolaus

$46

Buy

129.77%

Upside

Reiterated

08/14/25

Stifel Nicolaus Sticks to Their Buy Rating for Neurogene (NGNE)

Albert Lowe

Craig-Hallum

―

Buy

―

Reiterated

08/13/25

Craig-Hallum Sticks to Their Buy Rating for Neurogene (NGNE)

Ritu Baral

TD Cowen

―

Buy

―

Reiterated

08/12/25

Positive Outlook for Neurogene: Buy Rating Affirmed Amid Clinical Progress and Strong Financial Position

Sami Corwin

William Blair

―

Buy

―

Reiterated

08/12/25

William Blair Sticks to Its Buy Rating for Neurogene (NGNE)

Mani Foroohar

Leerink Partners

$72→$70

Buy

249.65%

Upside

Reiterated

08/12/25

Mitchell Kapoor

H.C. Wainwright

$45

Buy

124.78%

Upside

Reiterated

08/12/25

Evan Seigerman

BMO Capital

$22→$26

Buy

29.87%

Upside

Reiterated

06/30/25

Optimistic Outlook for Neurogene's NGN-401 in Rett Syndrome Treatment Boosts Buy Rating

Joel Beatty

Robert W. Baird

$38→$24

Hold

19.88%

Upside

Downgraded

05/16/25

Cautious Hold Rating on Neurogene Due to Regulatory Uncertainty and Data Quality Concerns for NGN-401

Dex Genotek

TR | OpenAI - 4o

―

Sell

―

Reiterated

05/01/25

AI Generated ArticleAI Generated Article

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

xxx

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Neurogene

1 Month

xxx

Success Rate

7/10 ratings generated profit

Average Return

+5.01%

reiterated a xxx

rating 17 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 1 Month would result in 70.00% of your transactions generating a profit, with an average return of +5.01% per trade.

3 Months

xxx

Success Rate

9/10 ratings generated profit

Average Return

+20.81%

reiterated a xxx

rating 17 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 3 Months would result in 90.00% of your transactions generating a profit, with an average return of +20.81% per trade.

1 Year

Paul MatteisStifel Nicolaus

Success Rate

8/14 ratings generated profit

Average Return

+1.64%

reiterated a buy rating 15 days ago

Copying Paul Matteis's trades and holding each position for 1 Year would result in 57.14% of your transactions generating a profit, with an average return of +1.64% per trade.

2 Years

xxx

Success Rate

4/9 ratings generated profit

Average Return

-12.42%

reiterated a xxx

rating 17 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 2 Years would result in 44.44% of your transactions generating a profit, with an average return of -12.42% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

NGNE Analyst Recommendation Trends

Rating

Apr 25

May 25

Jun 25

Jul 25

Aug 25

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, NGNE has received 18 Buy Ratings, 0 Hold Ratings, and 0 Sell Ratings. NGNE average Analyst price target in the past 3 months is 46.75.

Each month's total comprises the sum of three months' worth of ratings.

NGNE Financial Forecast

NGNE Earnings Forecast

Next quarter’s earnings estimate for NGNE is -$1.25 with a range of -$1.54 to -$1.09. The previous quarter’s EPS was -$1.05. NGNE beat its EPS estimate 75.00% of the time in the past 12 months, while its overall industry beat the EPS estimate 57.18% of the time in the same period. In the last calendar year NGNE has Outperformed its overall industry.

NGNE Sales Forecast

Next quarter’s sales forecast for NGNE is $0.00 with a range of $0.00 to $0.00. The previous quarter’s sales results were $0.00. NGNE beat its sales estimates 0.00% of the time in past 12 months, while its overall industry beat sales estimates 46.90% of the time in the same period. In the last calendar year NGNE has Preformed in-line its overall industry.

NGNE Stock Forecast FAQ

What is NGNE’s average 12-month price target, according to analysts?

Based on analyst ratings, Neurogene’s 12-month average price target is 46.75.

What is NGNE’s upside potential, based on the analysts’ average price target?

Neurogene has 133.52% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is NGNE a Buy, Sell or Hold?

Neurogene has a consensus rating of Strong Buy which is based on 7 buy ratings, 0 hold ratings and 0 sell ratings.

What is Neurogene’s price target?

The average price target for Neurogene is 46.75. This is based on 7 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $70.00 ,the lowest forecast is $26.00. The average price target represents 133.52% Increase from the current price of $20.02.

What do analysts say about Neurogene?

Neurogene’s analyst rating consensus is a Strong Buy. This is based on the ratings of 7 Wall Streets Analysts.

How can I buy shares of NGNE?

Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing

Neurogene (NGNE) Stock Forecast & Price Target

NGNE Analyst Ratings

NGNE Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Neurogene

NGNE Analyst Recommendation Trends

NGNE Financial Forecast

NGNE Earnings Forecast

NGNE Sales Forecast

NGNE Stock Forecast FAQ

Become an Expert with TipRanks Premium

Detailed List of Analyst Forecasts